PE consolidation in orthopedics has slowed from its 2019-2022 peak but has not stopped – 14 active U.S. platform MSOs were operating in mid-2026. The decision to sell is irreversible. The evaluation deserves more structure than most groups bring to it.
Key Takeaways
- EBITDA multiples for midsized orthopedic group transactions have ranged from the high single digits to low double digits; larger platform acquisitions have run in the mid-teens – the multiple you are quoted means little without understanding how EBITDA is defined in the deal.
- Rollover equity – the 20 to 40 percent stake most PE deals retain for physician partners – is worth what the platform is ultimately worth at exit, and most physicians are poor positioned to evaluate that independently.
- The governance terms of an MSO deal – what decisions remain with physicians, what requires MSO approval, and what the exit terms look like – are as important as the headline multiple, and they are almost always more negotiable than the initial draft suggests.
- An optimized independent practice that has corrected its payer contracts, rationalized overhead, and built ancillary revenue is a fundamentally different financial proposition than the practice a PE buyer is evaluating today – building that model before the sale conversation gives you the comparison you need.
Private equity interest in orthopedics did not disappear when deal volume fell from its 2019-2022 peak. CT Acquisitions’ 2026 tracker counts 14 active PE-backed orthopedic MSO platforms operating in the U.S. market. The pipeline of acquisition conversations is slower than it was, and the terms have become more careful, but the offers are still arriving at orthopedic groups of meaningful size – and they are arriving at practices that have rarely done the analysis to evaluate them with the rigor the decision deserves.
The irreversibility is the starting point for any honest conversation about a PE transaction. You can always decline a PE offer and revisit the question in two or three years. You cannot reverse a transaction after closing, and the physician-owners who most regret their decisions are typically those who sold into a narrative – the multiple was compelling, the timing felt right, the platform story was persuasive – without a rigorous model of what they were giving up and what the rollover equity was actually worth.
The Physician Growth Partners Q4 2024 white paper on orthopedic PE noted that the post-2022 market had moved to extended hold periods and balance sheet restructurings at some platforms, reflecting the debt-driven acquisition structures that characterized the peak years. That context matters when evaluating rollover equity: the value of the stake you retain depends on the platform’s ultimate exit, and a platform bought at a high multiple in 2021 with significant leverage may be structurally constrained in ways the initial presentation does not surface.
Understanding What Is Actually Being Valued
PE transactions in orthopedics are priced as EBITDA multiples, and the first thing to understand is that EBITDA in this context is a number the buyer’s model constructs, not a number your accountant produces from your books. The buyer will normalize your EBITDA for physician compensation in excess of a defined market rate, for non-recurring expenses, for overhead they believe they can reduce post-acquisition, and for ancillary revenue they expect to add. The adjusted EBITDA is then multiplied by the agreed-upon factor to produce a transaction value. The quoted multiple is meaningful only in relation to the EBITDA definition, and the EBITDA definition is negotiable.
Midsized orthopedic group transactions have historically carried EBITDA multiples in the high single digits to low double digits; larger platform acquisitions have run in the mid-teens. Those ranges have compressed somewhat in 2024-2025 as debt costs increased and buyer underwriting became more conservative. The more useful question than “what multiple can I get?” is “what is my practice’s EBITDA as the buyer will define it, and what will I actually receive at closing versus what will I receive at a hypothetical future exit?” Both numbers require modeling, and the model should be built by someone who is not compensated based on whether the transaction closes.
The MSO Structure and What Physicians Actually Control
Most PE acquisitions in orthopedics use a management services organization structure to navigate corporate practice of medicine restrictions. The physician practice retains ownership of the clinical entity and the physician-patient relationship. The MSO, which is the PE-owned entity, acquires the non-clinical assets – equipment, real estate, management systems, billing – and contracts to provide management services to the practice in exchange for a management fee that captures the economics. In states with strong corporate practice prohibitions, the MSO structure is essential to the transaction’s legal viability. In states with more permissive rules, it is still the standard structure for how the economics flow.
The governance provisions of the MSO agreement determine what physicians can actually decide post-close. Employment decisions, capital expenditures above a threshold, payer contract negotiations, and practice expansions may all require MSO approval under the initial draft. These terms are negotiated, and they matter more in the long run than the multiple. A practice that sold at a good multiple but surrendered the ability to make clinical hiring decisions or to terminate a management agreement with reasonable notice has accepted operational constraints that the financial model does not capture. Read the governance provisions as carefully as the purchase price definition, and negotiate them as actively.
The rollover equity is worth what the platform is worth at exit. Before you accept it in lieu of cash, model the scenario where that exit takes seven years and the multiple has compressed. That scenario is not hypothetical.
Building the Independence Comparison
The most important thing most orthopedic groups do not do when evaluating a PE offer is build a credible model of what optimized independence looks like. The practice being evaluated by a PE buyer today is the practice as it currently operates – with whatever payer contracts, overhead structure, and ancillary revenue it currently has. The practice that has renegotiated its commercial contracts to market rates, corrected the overhead inefficiencies, and built a functioning ancillary line is a materially different financial proposition, and it is the basis on which an independence comparison should be made.
A meaningful independence model asks: if we spent eighteen months executing on payer contracting, overhead rationalization, and ancillary development, what would our physician income look like? What would practice value look like under a future sale, at a time of our choosing, with a platform built to attract a better transaction? That model does not always favor independence – there are practices where the PE offer is genuinely the better economic outcome. But it is the model you need to make the comparison honest, and it is almost never built before the LOI conversation begins.
If you are a practice in a mandatory TEAM market, the independence model also needs to account for the hospital-physician relationship dynamics that TEAM creates. An independent group that can demonstrate favorable episode cost metrics has genuine leverage with hospital partners. An independent group that has not thought through its TEAM strategy has a vulnerability the PE narrative will exploit.
From the Field
A seven-physician orthopedic group in the Midwest received a PE letter of intent in late 2024, with a headline multiple that generated significant partner interest. The group had not been actively managed financially – payer contracts had not been renegotiated in four years, overhead was tracking above the group’s own informal benchmark, and a PT ancillary line that had been under discussion for two years had never been modeled. Our fractional CFO engagement built the transaction model (what the physicians would actually receive at closing and at a modeled exit), then built the independence alternative: the implied income increase from payer contract corrections, the break-even model for the PT line, and the EBITDA improvement that would result from two years of disciplined overhead management. The independence model produced a higher projected physician income over a five-year horizon. The group declined the LOI, authorized the payer contracting work, and is currently building the PT line. Whether that decision proves correct depends on execution – but it was made with both options modeled rather than one.
The Role of Advisors, and What to Watch For
PE transactions in orthopedics involve investment bankers, healthcare attorneys, accountants, and practice management consultants, and the compensation structures of most of them create a directional bias toward closing. The banker is paid at closing. The attorney doing the deal work is paid for deal work. Even a consultant engaged to evaluate the deal may have a relationship with the PE platform that creates conflicts worth surfacing.
Find an advisor who is compensated for the quality of the analysis rather than for the outcome of the transaction. A consultant can build the transaction model and the independence alternative and hand them to you to evaluate. If you have partners with the analytical capacity to stress-test both models and run the governance negotiation, that may be the right scope. A fractional CFO engaged for this decision works inside your financials with your accountant, builds both models from your actual operating data, and stays through the LOI negotiation to make sure the terms align with what was modeled. The analysis is only useful if it is based on your actual numbers, and getting to your actual numbers requires access to your systems – not a request for a data export.
State law adds complexity here as well. The corporate practice of medicine doctrine varies significantly across states. The enforceability of the MSO’s operational provisions and the regulatory treatment of the structure in your state are questions for healthcare counsel licensed where you practice. Build that review into the timeline, not as a final-step check but as an early input into what the structure can and cannot do.
Sources
- Physician Growth Partners, State of Orthopedic Private Equity Q4 2024 — https://physiciangrowthpartners.com/white-paper/state-of-orthopedic-private-equity-q4-2024/
- CT Acquisitions, Orthopedics PE Roll-Up Tracker 2026 — https://ctacquisitions.com/guides/orthopedics-pe-rollup-tracker-2026/
- Stout, 2026 Industry Outlook: Orthopedic Practices and Ancillary Services — https://www.stout.com/en/insights/industry-update/2026-industry-outlook-orthopedic-practices-ancillary-services
- MGMA, 2025 Provider Compensation and Productivity Data Report — https://www.mgma.com/2025-provider-compensation
More in the Orthopedics Series
- Building Ancillary Revenue in Orthopedics: Imaging, PT, and ASC — the ancillary revenue model that adds durable income without adding clinical hours.
- Payer Contracting in Orthopedics: Fee Schedules, Bundles, and TEAM — what your commercial contracts actually pay and how the mandatory TEAM bundled model changes the math.
- Orthopedic Physician Compensation: wRVUs, Conversion Factors, and What Goes Wrong — the compensation model that pays for performance without generating partner disputes.
- Block Time and Clinic Flow: The Throughput Problem Most Orthopedic Groups Ignore — the scheduling and block time changes that increase surgical volume without adding a surgeon.